A pproximately 1500 cases of malaria are reported annually in the United States (1) . These cases are not endemic to the United States but occur in persons with a history of recent travel to or residence in malariaendemic areas. Roughly 10% of U.S. malaria cases are considered severe by World Health Organization (WHO) criteria (2, 3) , and most are caused by Plasmodium falciparum (4 -7) . Patients with severe malaria are at risk for life-threatening complications, including renal failure, the acute respiratory distress syndrome (ARDS), severe hemolytic anemia, and cerebral malaria. Among these, cerebral malaria is arguably the most dire because it can present rapidly, often with minimal warning signs, and has a mortality rate of 15% to 30% with treatment and 100% without treatment (2, 4, 8 -10) . The only U.S. Food and Drug Administration (FDA)-approved treatment for severe malaria in the United States is quinidine, which is a stereoisomer of quinine that was once routinely used in hospitals as a cardiac antiarrhythmic medication (11, 12) . With the development of newer antiarrhythmic agents, many hospitals have removed quinidine from their pharmacies (13, 14) . Even when quinidine can be obtained, its intravenous regimen is complex and requires dosage adjustments and careful monitoring in an intensive care unit (ICU) (15) (16) (17) .
Artemisinin derivatives have been studied for their antimalarial properties since the early 1970s (18) , with a mechanism of action hypothesized to involve the production of oxygen radicals that interfere with parasite function (19) . Among the artemisinins, artesunate is the most widely used because it can be delivered intravenously with a reliable pharmacokinetic profile (20, 21) . Artesunate is a lifesaving drug that kills most malaria parasites very rapidly; further, any residual parasites are eliminated by postartesunate treatment with a follow-on oral antimalarial drug (2) . Artesunate has been proven superior to quinine against malaria in 2 large studies in endemic regions (9, 10) , and the drug is currently recommended as the first-line treatment for severe malaria by the WHO (2) . In the developing world, artesunate is now being used in the initial treatment of severe and complicated malaria caused by P. falciparum (22) . The product in use, however, is not manufactured according to current good manufactur-ing practice (CGMP) guidelines and is not FDAapproved for use in the United States (22) .
Since 2004, the Walter Reed Army Institute of Research has been developing a novel CGMP formulation of intravenous artesunate that has pharmacokinetics similar to preparations that do not follow CGMP (21, 23) . This drug has been successfully tested in phase 1 (21, 24) (25) . To assess the safety, tolerability, and clinical benefit of intravenous artesunate among U.S. patients with severe and complicated malaria, we evaluated medical records for patients enrolled in this IND protocol from 1 January 2007 to 31 December 2010.
METHODS

Design and Conduct
We completed a retrospective analysis of clinical data from U.S. patients with severe or complicated malaria who received intravenous artesunate according to 0  12  24  36  48  60  72  84  96  108  120  132  144  156  168  180 
EDITORS' NOTES Context
In the United States, the only U.S. Food and Drug Administration-approved drug for treatment of severe malaria is quinidine gluconate, which has substantial adverse effects and limited availability.
Contribution
Among patients with severe malaria who could not receive quinidine, artesunate had an acceptable efficacy and safety profile. No deaths occurred, and most adverse events were considered to be due to malaria rather than artesunate.
Caution
The study was not a randomized trial of artesunate versus other therapies but rather an investigational new drug protocol.
Implication
In patients with severe malaria, artesunate seems to be an attractive alternative to quinidine. 
Treatments
The Walter Reed Army Institute of Research supplied artesunate to the CDC as a sterile, dry-filled powder that was prepackaged with a phosphate buffer diluent for reconstitution. When a treating physician contacted the CDC malaria hotline (telephone: 770-488-7788 or 770-488-7100 after hours), artesunate was released if all CDC-060 enrollment criteria were met. Artesunate was shipped to the treating hospital rapidly from 1 of 9 CDC quarantine stations located across the United States. On receipt at the treating hospital, artesunate was to be reconstituted and administered in 4 weight-based doses (2.4 mg/kg), with the first dose infused immediately and the remaining 3 doses given at 12, 24, and 48 hours after the first. After their last dose, patients waited a minimum of 4 hours before commencing follow-on oral antimalarial therapy (not supplied by the CDC). The treating physician chose the follow-on antimalarial. Patients were to be treated in a hospital ICU, where they received appropriate concomitant medications and supportive treatments. However, other antimalarials were to be stopped during the period of artesunate administration. Kaplan-Meier survival analysis of the 87 evaluable patients.
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Patients
To be eligible for artesunate treatment under CDC-060, a patient must have met at least 1 criterion in each of 3 groups of enrollment criteria, which were designated as A, B, and C. Group A criteria required microscopic confirmation of malaria or a strong clinical suspicion of severe malaria when microscopic diagnosis was unavailable. Group B criteria confirmed the patient's need for intravenous treatment because of 1 or more of the following: inability to tolerate oral medications, high-density parasitemia (≥5%), or evidence of severe malaria (impaired consciousness, seizures, circulatory collapse or shock, pulmonary edema or ARDS, acidosis, acute renal failure, abnormal bleeding or disseminated intravascular coagulation, jaundice, or severe anemia with a hemoglobin level <70 g/L). Group C criteria verified the patient's need for artesunate because of at least 1 of the following factors: problems with quinidine availability, inefficacy (parasitemia >10% of baseline value at 48 hours after starting intravenous quinidine), intolerance, or contraindications. Patients were excluded if they had a known allergy to artesunate.
End Points
Although efficacy was not formally assessed, changes in specific clinical benefit variables were treated as secondary outcomes. Clinical benefit end points included time to negative parasitemia, time to follow-on oral therapy, time to discharge from the ICU, and change in group B criteria versus baseline. For each group B criterion present at baseline, daily determinations were made about whether the criterion had resolved, had improved, had deteriorated, or was unchanged.
Safety was assessed from data obtained from clinical assessments, laboratory measurements, adverse events (AEs), and deaths. Physical examination findings and AEs were coded according to the Medical Dictionary for Regulatory Affairs, version 14.0, and AE severity was graded based on the Common Terminology Criteria for Adverse Events, version 3.0. An AE's relationship to artesunate was determined by a majority consensus of the CBEC.
Statistical Analysis
Frequency tables were used to summarize categorical data, and continuous variables were summarized using descriptive statistics. The 95% CIs for outcomes and AE rates were reported. Changes in group B criteria were presented as the frequency and percentages of patients who had changes since baseline. Subgroup analyses of the data were done by segregating patients according to the following variables: baseline level of hepatic impairment (as measured by the Model for End-Stage Liver Disease formula) (26) , baseline level of renal impairment (as measured by the estimated glomerular filtration rate) (27), and baseline presence of markers for cerebral malaria (such as seizures, impaired consciousness, or need for ventilator support). Additional subgroup analyses were done for patients with concurrent antimalarial use during artesunate administration and those with quinidine exposure at any time before or during artesunate administration. Results of the subgroup analyses were displayed using KaplanMeier survival curves and compared using the log-rank, Wilcoxon rank-sum, and Tarone-Ware tests for statistical significance. All calculations were done using SAS software, version 9.2. 
Role of the Funding Source
The Office of the Surgeon General, Department of the U.S. Army, had oversight over the design and conduct of the study; collection, analysis, and interpretation of the data; and in the preparation, review, and approval of the manuscript for publication.
RESULTS
Patients
A total of 128 patients from U.S. hospitals was enrolled in the protocol during the period studied. Among these, 102 consented to artesunate treatment and received at least 1 dose of the drug. This group was considered the safety population and included 62 (61%) men and 40 (39%) women. Of these, 64 (63%) were black or African American, 26 (25%) were white, 9 (9%) were Asian, and 3 (3%) did not disclose their race. The mean age was 38.1 years (range, 1 to 72 years), with 92 adults (aged ≥15 years) and 10 children. Of the 102 patients, 87 were considered evaluable after review by the CBEC found that they met at least 1 criterion each from groups A and B and had confirmed P. falciparum. Two patients did not meet group A criteria, 4 did not meet group B criteria, and 12 were infected with a different species of Plasmodium or an unknown species.
Malaria was confirmed by microscopy in 96% of the safety population, and mean baseline parasitemia was 13.8%. The most common reason for requiring parenteral treatment was parasitemia of 5% or more (present in 66%) of patients, followed by jaundice in 47%, and inability to tolerate oral medications in 35%. The main reason patients received artesunate was that it was available faster than quinidine (61% of the cases). Consistent with group C criteria, 46 patients had prior exposure to quinidine, most of whom had received quinidine for 1 day before beginning artesunate.
The baseline clinical status of patients was as follows: 14% presented with severe or life-threatening renal impairment, 17% had severe or life-threatening liver impairment, and 35% had markers for cerebral malaria. Further, all 3 pregnant patients presented in their third trimester. Patients had other concurrent medical conditions, including diabetes (n = 11), asthma (n = 5), asplenia (n = 2), HIV infection (n = 2), hepatitis A (n = 1), hepatitis B (n = 1), and glucose-6-phosphate dehydrogenase deficiency (n = 1).
Treatment Adherence
In the safety population, 93 (91%) of 102 patients completed artesunate treatment. Of the 9 (9%) who did not, 5 had evidence of cerebral malaria at baseline and died before all 4 doses of artesunate could be administered. Contrary to the CDC-060 protocol, 1 patient received concomitant quinidine during artesunate dosing and an additional 45 patients were administered concomitant antimalarial medications other than quinidine while receiving artesunate. The most commonly used concomitant antimalarial was doxycycline (used in 35 patients).
For oral follow-on treatment, 41 (40.0%) patients received atovaquone-proguanil, 19 (18.6%) doxycycline, 5 (4.9%) clindamycin, 3 (2.9%) primaquine, and 2 (2.0%) mefloquine. The remaining 32 patients could not yet tolerate oral medications at day 7 of follow-up.
Clinical Benefit
Among the 87 evaluable patients, the median time to negative parasitemia was 42.7 hours. No differences in time to negative parasitemia were seen in the subgroup analyses (that is, baseline level of renal or hepatic impairment or baseline markers for cerebral malaria). The 38 evaluable patients who received concurrent antimalarials during artesunate administration had no statistically significant difference in time to neg- 
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Intravenous Artesunate for Severe Malaria ative parasitemia ( Figure 1 ) compared with the remaining 49 evaluable patients who did not receive concurrent antimalarials (43 hours vs. 51 hours, respectively; P = 0.942). The 43 evaluable patients with quinidine exposure had no statistically significant difference in time to negative parasitemia ( Figure 2 ) compared with the remaining 44 evaluable patients with no exposure (41 hours vs. 50 hours, respectively; P = 0.608).
In the safety population, 73 (72%) of 102 patients were discharged from the ICU within 7 days after beginning artesunate, with a median time to discharge of 4 days. Patients with severe liver disease or markers of cerebral malaria at baseline also left the ICU within 4 days. Among the 87 evaluable patients, a statistically significant difference ( P = 0.004) in time to discharge from the ICU was noted in those with quinidine exposure (median, 6 days) compared with those with no exposure (4 days). A similar finding, although not statistically significant, was seen in patients who had received concurrent antimalarials during artesunate administration (discharged in 5 days) compared with those who had not (discharged in 4 days; P = 0.256). In addition, patients with renal failure (severe or life-threatening estimated glomerular filtration rate) at baseline often remained in the ICU longer (median, 7 days) than those without this level of renal impairment (median, 4 days; P = 0.018).
Evaluation of time to follow-on antimalarial therapy was confounded by many patients who required exclusion from the analysis because their physicians had coadministered other antimalarial medications with artesunate. Of the 49 patients who could be evaluated for this end point, 39 (80%) successfully transitioned to oral antimalarial treatment in a mean of 3.8 days. No differences in time to start of oral therapy were seen in any of the subgroup analyses.
Analyses of changes in group B criteria ( Table 1 ) indicated how many of the clinical signs and symptoms of severe malaria improved or resolved in patients by day 3 of artesunate treatment. Several of the signs and symptoms completely resolved and were no longer followed by day 3, which made exact quantification difficult. Nevertheless, we concluded that artesunate exhibited clinical benefit. Exceptions were patients with ARDS, acute renal failure, or abnormal bleeding.
Safety
Seven patients died, with all deaths attributed to the severity of malaria rather than to artesunate. All of the deceased patients ( Table 2 ) had evidence of cerebral malaria and moderate to severe hepatic injury at baseline, and most (5 of 7) died before their artesunate regimen could be completed. Five had baseline hyperparasitemia ranging from 12% to 90%, 2 were older persons (aged >70 years), 2 were diabetic, and 1 had concurrent HIV infection.
A total of 278 AEs were reported (Table 3) , with 92.2% of patients having at least 1 AE. The most commonly reported AE was anemia (65% of patients), followed by increased hepatic enzyme levels (49%), thrombocytopenia (18%), hyperbilirubinemia (14%), acute renal failure (10%), and ARDS (8%). Most AEs (55%) were assessed as grade 1 (mild) or grade 2 (moderate) in severity, 25% were grade 3 (severe), and 20% were grade 4 (life-threatening). Further, 30% of patients (31 of 102) had a grade 4 AE, with the most frequently reported being anemia (13 reports), followed by respiratory failure, collapse, or ARDS (9 reports). No grade 4 AE was considered "definitely" related to artesunate by the CBEC.
Of the 3 pregnant patients, 1 delivered before beginning artesunate treatment. The remaining 2 received treatment while pregnant, had no grade 4 AEs, and had vaginal delivery of healthy infants within 1 month after recovering from malaria.
One of the 2 enrolled patients with concurrent HIV died, as did 2 of the 11 diabetic patients treated with artesunate. No deaths occurred among patients with concurrent hepatitis A or B virus infection, asthma, Because the protocol permitted concomitant medications (other than antimalarials) to treat the clinical manifestations of severe malaria, substantial polypharmacy occurred. More than 100 concomitant medications were administered (Appendix Table, available at www.annals.org), including acetaminophen (91 patients) or nonsteroidal anti-inflammatory drugs (53) for fever and pain; cephalosporins (56), vancomycin (34), or penicillins (26) for concurrent bacterial infections; ondansetron for nausea and vomiting (51); and anticoagulants for thrombosis prophylaxis (31) . No drugdrug interactions were reported.
DISCUSSION
Overall, European surveillance networks (TropNet and SIMPID data) have reported a case-fatality rate of about 15% for severe imported malaria (28) . Although artesunate has not yet been studied widely against severe malaria in Europe (29) , quinine treatment resulted in fatality rates of 8% to 11% in studies in France (30, 31) and the United Kingdom (32) . In comparison, the mortality rate was only 6.9% (7 of 102 patients) when artesunate was used in CDC-060, with all deaths being related to the consequences of severe malaria. In addition, advanced age (33, 34) or concurrent HIV infection (35) probably contributed to the fatal outcomes of 3 patients.
In general, AEs were consistent with symptoms expected in patients with severe malaria (36) . Anemia and increased hepatic enzyme levels, the most frequently reported AEs overall, are common in persons with severe malaria and may be attributed to the disease process alone (31, (37) (38) (39) . Other grade 4 AEs (for example, thrombocytopenia, ARDS, acute renal failure, and cerebral edema) are also well-documented complications of severe malaria (32, 36 -39) .
The data captured in Table 1 indicated that the clinical signs and symptoms of severe malaria improved or resolved in several patients by day 3. Exceptions were patients with ARDS, acute renal failure, or abnormal bleeding, all of which are complications of malaria that carry an extraordinary risk for poor outcomes (40, 41) . Therefore, these patients would not be expected to recover quickly.
Overall, based on the evaluation of multiple variables, artesunate was clinically beneficial to patients with severe and complicated malaria. Artesunate produced rapid and effective parasite clearance, with a median time to negative parasitemia of 42.7 hours. However, these reported parasitemia estimations were made at the clinical sites and not verified for accuracy. Parasite clearance times may have been shorter if laboratories were including gametocytes in their parasitemia estimations (42) . In addition, although there are reports of prolonged parasite clearance times with artemisinin-based therapy from Southeast Asia that suggest resistance (43) , this is not the case in Africa or other malaria-endemic areas. Imported cases of severe malaria in the United States still respond rapidly to artesunate therapy.
No differences in time to negative parasitemia were seen in any of the subgroup analyses, including 
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Intravenous Artesunate for Severe Malaria patients with prior exposure to quinidine or those given concomitant antimalarials. Median time to starting a follow-on oral therapy was 4 days, and this was independent of baseline renal, hepatic, or neurologic status. Median time to discharge from the ICU was also 4 days, even for patients who had severe liver disease or cerebral malaria at baseline. This finding, in particular, highlights the clinical benefit of artesunate among patients with dire clinical presentations. In CDC-060, artesunate was administered in a treatment context of intense polypharmacy. More than 100 concomitant medications were used. Further, additional pharmacologic risks were inherent to the ICU environment, including high and prolonged dosing regimens, adjuvant toxicity, and the effect of end-organ dysfunction (44) . Despite these challenges, artesunate was used safely in a clinical context that presented a high risk for drug-drug interactions.
One potential limitation of this evaluation was the relatively brief 7-day follow-up, which did not permit the tracking of any potential late-presenting safety issues. Recent reports have been published about delayed hemolysis in some patients, particularly those with hyperparasitemia, who received artesunate for severe malaria. The mechanism is not entirely understood. Although no cases reported have been fatal, the WHO recommends following patients treated with artesunate for up to 1 month to assess for hemolytic anemia; any patients who develop hemolytic anemia should be reported to an appropriate pharmacovigilance center (for example, the FDA) (45).
The aim of the CDC-060 IND protocol was to make CGMP artesunate available to U.S. patients with severe and complicated malaria for whom quinidine was problematic or unavailable. Data abstracted from CDC-060, as presented here, indicate that artesunate was safe and clinically beneficial for most U.S. patients who were treated with the drug during the targeted period, which supports the use of artesunate as a quinidine alternative. 
